Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Clinical trials with major tranquilizers must take into account the clinical features of patients with schizophrenia and pharmacokinetic and pharmacodynamic properties of the drug. The objectives of the trial must be carefully defined so that appropriate selection criteria for patients, rating instruments and dosage schedules can be selected. It is useful to monitor physiological and biochemical actions of major tranquilizers as well as the clinical effects.
 ...
PMID:Assessment of drugs in schizophrenia. Basic trial design. 0 64

The Collaborative Neuropsychological Study of Polydrug Users performed extensive neuropsychological assessments on 15 polydrug users 3 weeks after their enrollment in each of eight polydrug demonstration programs. Fifty-six (37%) of these subjects exhibited neuropsychological deficit. This deficit was partially related to increasing age, poor education and premorbid medical risk factors. The deficit was also associated with extensive and intensive use of two classes of drugs: sedatives (sleeping pills and minor tranquilizers) and opiates (heroin and other narcotic drugs). Seventeen (26%) of a comparison group of 66 psychiatric in-patients and day patients also demonstrated age- and education-correlated neuropsychological deficit. For these patients impairment was also related to lifetime experience with antipsychotic drugs and (perhaps) with clinical diagnosis of schizophrenia. Although both polydrug users and psychiatric patients revealed serious psychopathology as measured by the MMPI, the pattern of the neuropsychological test findings suggested that psychopathology alone did not account for impairment. The 3 month follow-up which is in progress should delineate further the time course and enduring features of neuropsychological deficit among polydrug users, and may establish more clearly the relationship of sedative and opiate use to such impairment. Changes in psychopathological status of both polydrug users and psychiatric patients should also help to clarify the influence of this variable on neuropsychological findings.
 ...
PMID:Neuropsychological deficit in polydrug users. A preliminary report of the findings of the collaborative neuropsychological study of polydrug users. 1 18

A hypothesis is put forward in regards to what is called "chronic schizophrenia" that those observations which suggest a continuing disease process may turn out not to be intrinsic facets of schizophrenia as a neurochemical instability but rather neurotic reactions to the acute schizophrenic process. The hypothesis goes on to suggest that this reaction to the acute psychosis is such as to constitute a traumatic neurosis and that while controlling the psychosis with an "umbrella" of major tranquilizers, it is possible to resolve this neurosis. Resolution of the neurosis requires a particular approach to therapy. This is a hypothesis which is very much open to experimental examination and one which may, if proven, markedly affect the postpsychosis management of schizophrenia.
 ...
PMID:The trauma of being psychotic: a neglected element in the management of chronic schizophrenia? 1 48

The efficacy of psychopharmacological treatment modalities and comatose methods was studied in the therapy of patients with slowly progressive schizophrenia, the clinical picture of which was characterized by cenestho-hypochondriacal disturbances (155 cases). The use of high doses of neuroleptics, atropine and insulin comas in these cases were ineffective. A positive compliance to therapy was attained in the treatment by tranquilizers of the benzodiazepine series, especially by a parenteral administration. The best results were demonstrated in the treatment of pseudoneurotic hypochondria. The therapeutic reluctancy increased in the cenestho-algic syndrome and in the syndrome of "rigid" hypochondria. The most effective in these cases was a combined therapy by tranquilizers (parenteral administration) and small doses of neuroleptics.
 ...
PMID:[Psychopharmacotherapy of slowly progressive hypochondriacal schizophrenia]. 4 44

The results of the qualitative but particularly the quantitative EEG-studies indicate that 1. The EEG of adult schizophrenics is characterized by an appearance of excessive fast activity along with some slow waves and the lack of alpha-activity. 2. Excessive fast activity and lack of alpha-waves have also been found in the EEGs of psychotic children and most interestingly in children whose parents (particularly the mother) are schizophrenic (high risk children). 3. Based on the studies during sleep and investigations with neuroleptics, it was established that the origin of the excess fast activity in schizophrenia cannot be the muscle potential. Particularly the excess fast activity in high risk children for schizophrenia goes against the muscle potential hypothesis. 4. The quantitative EEG changes seen in schizophrenia show similarity to those seen after hallucinogenic compounds particularly after anticholinergic hallucinogenics. 5. All neuroleptics (major tranquilizers) produce quantitative EEG alterations which are almost diametrically opposite to those seen in schizoprenia.
 ...
PMID:[Qualitative and quantitative EEG-findings in schizophrenia (author's transl)]. 41 42

Delusions have traditionally been regarded as unmodifiable false beliefs. Both Freud (1911) and Jaspers (1968) argue that there is a unidirectional relationship between a delusional belief and consensually validatable realtiy: the delusion structures reality in accordance with the delusion's demand. In contrast, we postulate that there is a bidirectional interaction between the delusion and external events. We believe that external events might modify the rigid belief when there is a dramatic incongruity between specific beliefs and selected events. The following investigation was motivated by a desire to understand more clearly how some overtly delusional patients come to lose their delusions during the course of treatment for schizophrenia. Do delusions simply melt away under the influence of major tranquilizers, or does the delusional patient play some active part in assessing the validity of this belief?
 ...
PMID:A cognitive investigation of schizophrenic delusions. 50 12

Seventy-nine "phasic type" of schizophrenics (38 males, 41 females), who in their progress of schizophrenia had a certain dilapidation of personality, were observed and treated for more than four years and were investigated as to the intervals of their recurrences. The recurrence totaled 198. It was characteristic of periodic occurences that 61.1% of them occurred within an interval of eight to eleven months (about 240-330 days) and 10.6% of them occurred within an interval of approximate multiples of eight to eleven months (as measured from the start of one recurrence period to the start of the next). The interval between recurrences was not markedly affected by seasonal changes, which raised or lowered the temperature and lengthened or shortened the day. Nor was it affected by tranquilizers, such as phenothiazine-derivatives, butyrophenone-derivatives, or by the psychogenic moment (though the picture of recurrences might be affected by all of these). The rhythm of recurrences of the "phasic type" of schizophrenia seems to be endogenous in free-running nature, as if schizophrenics live in an empty world.
 ...
PMID:Periodicity of recurrence of 'phasic type' of schizophrenia. 117 69

The effects of LSD are characterized by a number of disturbances of perception and experience, which can be observed in the fields of visual, spatial and temporal perception and of affectivity. We also see disturbances of experience, which can otherwise be observed only in psychoses, for example reduction or change of cognitive functions, but also depersonalization and euphoria. In atypical courses of intoxication ("horror-trips") anxiety and excitement are predominant. Atypical courses of intoxication may be interrupted by "talk down" and additional application of tranquilizers. In a certain number of LSD-users in our clinic we saw psychoses. We classify them into flash-backs, exogenic (toxic) psychoses and so-called "endoform psychoses". The latter implies three possible constellations: accidental coincidence of LSD-use and psychosis; pre-existing psychosis with symptomatic use of LSD as an attempt of self-treatment; finally the onset of a psychosis may be triggered by the use of the halluzinogen. From the symptomatological cross-section they cannot reliably be distinguished from real schizophrenia. An independent nosological unit "LSD-psychosis" does not seem to exist.
 ...
PMID:[Problems of toxic psychosis as illustrated on the example of the so-called LSD psychosis]. 119 15

The previous works of the author demonstrated the clinical heterogeneity of Gilles de la Tourette's syndrome (GTS). Based on statistical treatment of the efficacy of 138 courses of the treatment with benzodiazepine tranquilizers, neuroleptics, antidepressants, and anticonvulsants, methods of the individualized treatment of GTS were elaborated. It is recommended that low doses of neuroleptics (orap, haloperidol) be applied in patients with typical GTS. Schizophrenia associated with Tourette-like disorders requires the use of higher doses of neuroleptics and, in some cases, of the combined therapy. In encephalopathy accompanied by Tourette-like disorders, the treatment with anticonvulsants and benzodiazepine tranquilizers turned out most effective.
 ...
PMID:[Differential therapy of Gilles de la Tourette's syndrome]. 166 19

The classification of psychoactive drugs into minor tranquilizers (i.e. antianxiety drugs) and major tranquilizers (i.e. antidepressants, antimaniacs and antipsychotics) is based on clinical symptom rating scales. The group of symptoms in these scales of anxiety, depression, mania and schizophrenia has a shared phenomenology in the sense that the symptoms can be ordered from less to more severe. The inter-observer agreement when using these scales is adequate as agreement is of 80% or higher. By use of rating scales it has been found in controlled clinical trials that minor psychiatric disorders such as anxiety states without depression have a good outcome of placebo in 60 to 65%. In depressive disorders placebo has a good outcome in 20-45%, but in the elderly depressed patient the placebo effect is poorest (25%). Antidepressants have a good outcome in 60-75%, but in the elderly depressed patients only in 50%. In other words the drug-placebo difference is around 25%. In the major psychiatric disorders such as mania and schizophrenia the drug-placebo difference is around 50%. The use of clinical symptom scales in evaluating side-effects of psychoactive drugs is increasing. However, also non-clinical or laboratory tests have an important role in measuring side-effects, especially in motor skills related to car driving. The use of mentally healthy volunteers in measuring side-effects of major tranquilizers seems inadequate. As yet no biological methods to measure clinical effects of the tranquilizers have been developed for practical use.
 ...
PMID:Methods of evaluation of psychoactive drugs. 269 5


1 2 3 Next >>